Literature DB >> 30272400

Schedules of Controlled Substances: Placement in Schedule V of Certain FDA-Approved Drugs Containing Cannabidiol; Corresponding Change to Permit Requirements. Final order.

.   

Abstract

With the issuance of this final order, the Acting Administrator of the Drug Enforcement Administration places certain drug products that have been approved by the Food and Drug Administration (FDA) and which contain cannabidiol (CBD) in schedule V of the Controlled Substances Act (CSA). Specifically, this order places FDA-approved drugs that contain CBD derived from cannabis and no more than 0.1 percent tetrahydrocannabinols in schedule V. This action is required to satisfy the responsibility of the Acting Administrator under the CSA to place a drug in the schedule he deems most appropriate to carry out United States obligations under the Single Convention on Narcotic Drugs, 1961. Also consistent therewith, DEA is adding such drugs to the list of substances that may only be imported or exported pursuant to a permit.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30272400

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  7 in total

Review 1.  Concerns of Patients With Cancer on Accessing Cannabis Products in a State With Restrictive Medical Marijuana Laws: A Survey Study.

Authors:  Vinita Singh; Ali J Zarrabi; Kimberly A Curseen; Roman Sniecinski; Justine W Welsh; Anne M McKenzie-Brown; Wendy Baer; Theresa W Gillespie
Journal:  J Oncol Pract       Date:  2019-08-23       Impact factor: 3.840

2.  Six policy lessons relevant to cannabis legalization.

Authors:  Chelsea L Shover; Keith Humphreys
Journal:  Am J Drug Alcohol Abuse       Date:  2019-03-14       Impact factor: 3.829

3.  Challenges for Clinical Cannabis and Cannabinoid Research in the United States.

Authors:  Ziva D Cooper; Donald I Abrams; Steven Gust; Alejandro Salicrup; Douglas C Throckmorton
Journal:  J Natl Cancer Inst Monogr       Date:  2021-11-28

4.  Urinary Pharmacokinetic Profile of Cannabinoids Following Administration of Vaporized and Oral Cannabidiol and Vaporized CBD-Dominant Cannabis.

Authors:  Tory R Spindle; Edward J Cone; David Kuntz; John M Mitchell; George E Bigelow; Ronald Flegel; Ryan Vandrey
Journal:  J Anal Toxicol       Date:  2020-03-07       Impact factor: 3.220

5.  Prevalence of cannabis use has significantly increased in patients with cyclic vomiting syndrome.

Authors:  Mohamed Tausif Siddiqui; Mohammad Bilal; Amandeep Singh; Sarah Olivier-Cabrera; Edward Lebovics; Beth Schorr-Lesnick; Brad Dworkin; Donald F Kirby
Journal:  Neurogastroenterol Motil       Date:  2020-01-28       Impact factor: 3.960

Review 6.  A Balanced Approach for Cannabidiol Use in Chronic Pain.

Authors:  Donovan A Argueta; Christopher M Ventura; Stacy Kiven; Varun Sagi; Kalpna Gupta
Journal:  Front Pharmacol       Date:  2020-04-30       Impact factor: 5.810

7.  Carbonyl Compounds in Mainstream Smoke of Hemp Cigarettes.

Authors:  Alexandra M Ward; Jon O Ebbert
Journal:  Cannabis Cannabinoid Res       Date:  2020-07-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.